Allogene Therapeutics, Inc. — Director's Dealing 2021

May 26, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Allogene Therapeutics, Inc. (ALLO)
CIK: 0001737287
Period of Report: 2021-05-24

Reporting Person: Chang David D (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-24	Common Stock	M	27410	$18.22	Acquired	2312279	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-24	Stock Option (Right to Buy)	$18.22	M	27410	Disposed	2030-03-18	Common Stock (27410)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1201108	Indirect
Common Stock	856044	Indirect
Common Stock	856044	Indirect

Footnotes

F1: Securities held in the name of the Chang 2006 Family Trust.

F2: Securities held in the name of the JEC 2019 Trust dated October 1, 2019.

F3: Securities held in the name of the RTC 2019 Trust dated October 1, 2019.

F4: 25% of the shares subject to the stock option shall vest on the first anniversary of the grant date, and the remaining shares shall vest in 36 equal monthly installments thereafter.